A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease
about
Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledgePotential for developing purinergic drugs for gastrointestinal diseasesNuclear cardiology: 2014 innovations and developmentsEffect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study.Safety and tolerability of regadenoson CMR.Regadenoson in Europe: first-year experience of regadenoson stress combined with submaximal exercise in patients undergoing myocardial perfusion scintigraphy.Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study.Regadenoson: a focused update.Advances in SPECT in evaluating coronary disease.Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies.Regadenoson stress for myocardial perfusion imaging.Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.Regadenoson in Myocardial Perfusion Study - First Institutional Experiences in Bosnia and Herzegovina.Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience.A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: a randomized controlled trial.Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials.Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma.Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson.Regadenoson for myocardial perfusion imaging: Is it safe?Regadenoson pharmacologic rubidium-82 PET: a comparison of quantitative perfusion and function to dipyridamole.
P2860
Q26829779-FE3C78BB-EA12-4D0D-84A2-AF76987F26DFQ27000719-EBCFAD16-D8FC-41D4-BF2D-B167A9BFCFAFQ28081835-6F9681A9-46B4-476F-B02A-02002F3B005FQ33561287-2A0DDF96-5C00-444D-A77B-7F74B79BDFE9Q33767994-6DB9BFD8-8E74-4CDC-BD71-AE2BC9E6F50AQ37554933-80AE3AC9-B8E5-4873-A6D4-DFDC4026A210Q37596745-CAE3BF1C-9DF9-4B27-8088-47525A9E8D98Q38066403-89DC0522-F16A-4FFE-AD43-46882810F795Q38231506-BFBF01FE-7D42-4D11-818D-356CB6568899Q38480969-F7C19CEA-D093-4AA0-8036-30FBEB8CBA14Q38660349-E98DAEC2-A5AD-4A72-BDDF-5EAAE42D9CD5Q39508932-C3000ED5-D487-474C-94CB-2587A76B5F2EQ40445363-C8AA8B48-2E67-4481-88C4-47806BD16D46Q40865264-83FFBAF4-D38F-4160-9BAF-F2AE81442C89Q45354603-FCB929C1-8E69-4A02-9C61-5AC47476AB05Q45833492-DFA448D3-EF50-4FEB-892B-5210058C4036Q46787401-E0AAD0EB-8C5B-4187-AE9D-F2688BFB0895Q47735877-C994B293-5786-4593-9FBD-FDB2092D7397Q48089138-B181AECD-28D4-46D4-BE10-4A0462A3E094Q48271472-86BCFC40-3367-4C52-A377-FAC08F5A3AD2Q53131056-4C5AAB27-F1BE-4079-BB39-661564B5F941
P2860
A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A randomized, double-blind, pl ...... obstructive pulmonary disease
@ast
A randomized, double-blind, pl ...... obstructive pulmonary disease
@en
type
label
A randomized, double-blind, pl ...... obstructive pulmonary disease
@ast
A randomized, double-blind, pl ...... obstructive pulmonary disease
@en
prefLabel
A randomized, double-blind, pl ...... obstructive pulmonary disease
@ast
A randomized, double-blind, pl ...... obstructive pulmonary disease
@en
P2093
P2860
P921
P1476
A randomized, double-blind, pl ...... obstructive pulmonary disease
@en
P2093
Bruce E McNutt
Bruce M Prenner
Kathleen Feaheny
Sarah Behm
Stan Bukofzer
P2860
P2888
P304
P356
10.1007/S12350-012-9547-4
P577
2012-04-07T00:00:00Z